Pharmacokinetics, safety, tolerability and efficacy of cotadutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, in phase 1 and 2 trials in overweight or obese participants of Asian descent with or without type 2 diabetes

What Was Tested

Researchers studied Glucagon and Cotadutide in this clinical trial, phase i publication.

Who Took Part

The study group was 61 adults.

PubMed indexes the participants as adults.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and parallel-group study.

Because people in this Glucagon study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Glucagon study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Glucagon could be set against what happens without it.

The Glucagon group and the comparison group ran side by side rather than switching.

The primary endpoint was safety.

Co-primary endpoints were safety/tolerability, change in glucose AUC0-4h and body weight.

What Was Measured

PubMed files the paper under topics including Diabetes Mellitus, Type 2, Glucagon, Glucagon-Like Peptide 1, Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptides, Hypoglycemic Agents and Obesity.

Author keywords: Asian, GLP-1 and glucagon receptor agonist, Japanese, MEDI0382, T2D and cotadutide.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Glucagon and Cotadutide in 61 adults.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2021 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Glucagon compound page and the Cotadutide compound page, all human trials.